Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Bioconjug Chem. 2015 Apr 6;26(7):1224–1236. doi: 10.1021/acs.bioconjchem.5b00070

Figure 5.

Figure 5

Data showing the effects of GRGDS ligand density on in vivo hemostatic function. Comparison between 1-hour survival (top) and blood loss (bottom) of lethal liver injury rat models after intravenous injection of (A) 40 mg/kg GRGDS-NP1 and (B) 5, 20, and 40 mg/kg GRGDS-NP100 demonstrates an 8-fold reduction in effective particle dosage (i.e. increased potency) when ligand density is increased 100-fold [reproduced with permission from 43,71]. However, adverse effects are observed at 20 and 40 mg/kg GRGDS-NP100 most likely due to saturation of GPIIb-IIIa receptors on platelets which would prevent platelet aggregation (C). (B) *P < 0.05 compared to saline.